Deploying new vaccines has always been a messy business of logistical hurdles, ethical questions, and amazing feats.   Take the first-ever vaccine campaign, Spain’s 19th century effort to stamp out smallpox in its far flung colonies.

We’ll be observing Martin Luther King Jr. Day on Monday, January 18 in the US so GHN will not be publishing. We’ll be back Tuesday with more news. 

Editor’s Note: This is the first of an occasional GHN series examining the health challenges that the new Biden administration must confront in its first 100 days.   The incoming Biden administration promises a vigorous, across-the-board reboot of the failed US…

A Chinese-made coronavirus vaccine has an efficacy rate just over 50%—far lower than the 78% anticipated, according to a Brazilian clinical trial conducted by São Paulo’s Butantan Institute.  

WHO investigators from 9 countries have arrived in Wuhan to look into the origins of the pandemic, following delays that triggered a rare rebuke from the agency.  

One Friday last month, I posted a map on Twitter. It drew immediate global attention, was seen by 8 million people, and has provoked strong responses and anger—and hopefully some soul-searching among those in governments and pharmaceutical companies.

For many detainees in US immigration facilities, the coronavirus was impossible to avoid. They were sleeping 3 feet apart with 36 people in a room.

“The virus took Grandma Delores first, silencing an 86-year-old voice that rang with Lakota songs and stories.”  

Among the many challenges facing President-elect Joe Biden upon his inauguration on January 20, the most urgent is the US COVID-19 response. How will things change? What will be his strategies and priorities?